| NCT Number | Conditions | Interventions | Sponsor/Collaborators | Phases | Start Date | Last Updated |
| NCT01234311 | Prostate Cancer | Drug: tasquinimod|Drug: Placebo | Active Biotech AB | Phase 3 | 2011-03-01 | 2015-10-02 |
| NCT02396368 | Prostate Cancer|Bone-only Metastatic Castration-Resistant Prostate Cancer (CRPC) | Drug: Tasquinimod|Radiation: Radium 223 | Sidney Kimmel Comprehensive Cancer Center | Phase 1 | 2015-03-01 | 2015-11-17 |
| NCT01048203 | Healthy | Drug: ABR-215050 | Active Biotech AB | Phase 1 | 2009-01-01 | 2014-08-26 |
| NCT01513733 | Prostate Cancer | Drug: tasquinimod|Drug: tasquinimod 0.25 mg; 0.5 mg|Drug: tasquinimod 0.25 mg; 0.5 mg; 1.0 mg | Andrew J. Armstrong, MD|Duke University | Phase 1 | 2012-01-01 | 2017-02-08 |
| NCT02159950 | Hormone-Resistant Prostate Cancer|Metastatic Prostate Carcinoma|Recurrent Prostate Carcinoma|Stage IV Prostate Cancer | Other: Laboratory Biomarker Analysis|Biological: Sipuleucel-T|Drug: Tasquinimod | Roswell Park Cancer Institute|National Cancer Institute (NCI)|Active Biotech AB | Phase 2 | 2015-01-01 | 2016-05-19 |
| NCT01743469 | Advanced or Metastatic Hepatocellular Cancer|Advanced or Metastatic Ovarian Cancer|Metastatic Renal Cell Cancer|Advanced or Metastatic Gastric Carcinoma | Drug: Tasquinimod | Ipsen | Phase 2 | 2012-12-01 | 2016-03-31 |
| NCT01732549 | Metastatic Castrate Resistant Prostate Cancer | Drug: Tasquinimod|Drug: Placebo | Ipsen | Phase 2 | 2013-01-01 | 2016-08-09 |
| NCT02057666 | Asian Chemo-nave Patients With Metastatic Castrate-resistant Prostate Cancer | Drug: Tasquinimod|Drug: Placebo | Ipsen | Phase 3 | 2014-01-01 | 2015-06-29 |
| NCT00560482 | Prostate Cancer | Drug: ABR-215050, tasquinimod|Drug: Placebo | Active Biotech AB | Phase 2 | 2007-12-01 | 2015-10-02 |
